There was no experience with overdosage of glofitamab in clinical trials.L45698
Glofitamab is a full-length bispecific monoclonal antibody with affinity for both CD20 and CD3 surface antigens found on B- and T-cells, respectively. It has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting T-cells directly to the surface of cancerous B-cells.L45698,A258488
Glofitamab was approved by Health Canada in March 2023 for the treatment of certain patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), becoming the first CD20/CD3 bispecific monoclonal antibody approved for DLBCL.L45768 The most common type of non-Hodgkin lymphoma,L45763 DLBCL is relatively sensitive to chemotherapy and generally responsive to first-line treatment regimens like CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)L45763 - despite this, as many as 40% of patients will experience relapsed or refractory disease.L45768,A258433 In the context of relapsed or refractory DLBCL, glofitamab provides an alternative treatment option for patients having failed other systemic therapies or for whom targeted therapies - such as CAR-T cell therapy - are inappropriate.
In June 2023, the FDA approved the use of glofitamab for the treatment of patients with relapsed or refractory DLBCL not otherwise specified or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy under accelerated approval based on response rate and durability of response.L47047,L47052
Glofitamab was granted conditional marketing authorization in July 2023 by the EMA for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. This approval is based on the positive results obtained from the phase I/II NP30179 study, where 35.2% of study participants achieved a complete response.L47451
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | The serum concentration of Diethylstilbestrol can be increased when it is combined with Glofitamab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Glofitamab. |
| Conjugated estrogens | The serum concentration of Conjugated estrogens can be increased when it is combined with Glofitamab. |
| Estrone | The serum concentration of Estrone can be increased when it is combined with Glofitamab. |
| Estradiol | The serum concentration of Estradiol can be increased when it is combined with Glofitamab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Glofitamab. |
| Ethinylestradiol | The serum concentration of Ethinylestradiol can be increased when it is combined with Glofitamab. |
| Mestranol | The serum concentration of Mestranol can be increased when it is combined with Glofitamab. |
| Estriol | Estriol may increase the thrombogenic activities of Glofitamab. |
| Estrone sulfate | The serum concentration of Estrone sulfate can be increased when it is combined with Glofitamab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Glofitamab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Glofitamab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Glofitamab. |
| Synthetic Conjugated Estrogens, A | The serum concentration of Synthetic Conjugated Estrogens, A can be increased when it is combined with Glofitamab. |
| Synthetic Conjugated Estrogens, B | The serum concentration of Synthetic Conjugated Estrogens, B can be increased when it is combined with Glofitamab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Glofitamab. |
| Esterified estrogens | The serum concentration of Esterified estrogens can be increased when it is combined with Glofitamab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Glofitamab. |
| Equol | Equol may increase the thrombogenic activities of Glofitamab. |
| Estetrol | The serum concentration of Estetrol can be increased when it is combined with Glofitamab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Glofitamab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Glofitamab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Glofitamab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Glofitamab. |
| Estradiol acetate | The serum concentration of Estradiol acetate can be increased when it is combined with Glofitamab. |
| Estradiol benzoate | The serum concentration of Estradiol benzoate can be increased when it is combined with Glofitamab. |
| Estradiol cypionate | The serum concentration of Estradiol cypionate can be increased when it is combined with Glofitamab. |
| Estradiol valerate | The serum concentration of Estradiol valerate can be increased when it is combined with Glofitamab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Glofitamab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Glofitamab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Glofitamab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Glofitamab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Glofitamab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Glofitamab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Glofitamab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Glofitamab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Glofitamab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Glofitamab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Glofitamab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Glofitamab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Glofitamab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Glofitamab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Glofitamab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Glofitamab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Glofitamab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Glofitamab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Glofitamab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Glofitamab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Glofitamab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Glofitamab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Glofitamab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Glofitamab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Glofitamab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Glofitamab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Glofitamab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Glofitamab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Glofitamab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Glofitamab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Glofitamab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Glofitamab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Glofitamab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Glofitamab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Glofitamab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Glofitamab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Glofitamab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Glofitamab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Glofitamab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Glofitamab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Glofitamab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Glofitamab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Glofitamab. |
| Hepatitis B immune globulin | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Glofitamab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Glofitamab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Glofitamab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Glofitamab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Glofitamab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Glofitamab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Glofitamab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Glofitamab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Glofitamab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Glofitamab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Glofitamab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Glofitamab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Glofitamab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Glofitamab. |
| Trastuzumab emtansine | The serum concentration of Trastuzumab emtansine can be increased when it is combined with Glofitamab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Glofitamab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Glofitamab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Glofitamab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Glofitamab. |
| Stamulumab | The risk or severity of adverse effects can be increased when Stamulumab is combined with Glofitamab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Glofitamab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Glofitamab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Glofitamab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Glofitamab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Glofitamab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Glofitamab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Glofitamab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Glofitamab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Glofitamab. |